Ribupatide (HRS9531): GEMINI-1 Weight Loss Results
Hengrui's once-weekly GLP-1/GIP dual agonist cut body weight by 17.7% at 48 weeks on the 6 mg dose in a 567-person phase 3 trial in China. Here is what the trial measured, what it did not, and how it stacks up against tirzepatide.
Code HIGHPEPTIDES takes 15% off at checkout: $80.75
Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
How It Works
Ribupatide is a chemically synthesised polypeptide that activates both GLP-1 and GIP receptor signalling in lab assays. That puts it in the same dual-agonist class as tirzepatide.
In the first-in-human study, the mean half-life was 7 to 8 days after repeated doses, which fits a once-weekly subcutaneous injection.
In a phase 1 trial of 90 healthy Chinese volunteers (single- and multiple-dose parts), the multiple-dose groups given four weekly doses lost 4.3 to 7.7 kg (6.7% to 9.6%) versus 1.2 kg (1.4%) on placebo, and fasting glucose fell with dose.
Gastrointestinal events rose with dose in GEMINI-1: 47.9% (2 mg), 58.2% (4 mg) and 63.1% (6 mg) versus 23.1% on placebo, mostly mild to moderate.
What the Data Shows
Is Ribupatide Better Than Tirzepatide?
Nobody has tested that yet. No trial has put ribupatide and tirzepatide in the same study. The viral "17.7% vs 17.5%" line sets the GEMINI-1 top dose next to the SURMOUNT-CN top dose. Both numbers are real, but they come from two separate trials with different lengths and different placebo groups, so they can only be read side by side, not as a ranking.
| Trial | Drug, top dose | Length | Weight change | Placebo | Placebo-adjusted |
|---|---|---|---|---|---|
| GEMINI-1 (China, n=567) | Ribupatide 6 mg | 48 weeks | −17.7% | −1.4% | −16.3 points |
| SURMOUNT-CN (China, n=210) | Tirzepatide 15 mg | 52 weeks | −17.5% | −2.3% | −15.1 points |
| SURMOUNT-1 (global, n=2,539) | Tirzepatide 15 mg | 72 weeks | −20.9% | −3.1% | not in abstract |
| Retatrutide phase 2 (n=338) | Retatrutide 12 mg | 48 weeks | −24.2% | −2.1% | not in abstract |
Sources: GEMINI-1 (PMID 43035098), SURMOUNT-CN (PMID 38819983), SURMOUNT-1 (PMID 35658024), retatrutide phase 2 (PMID 37366315). Retatrutide is a different drug class (it adds glucagon receptor activity), and its 48-week figure is a secondary end point from a phase 2 trial.
The two Chinese trials are closer than most cross-trial pairs: both enrolled adults without diabetes with a BMI of 28 or more (or 24 or more with a weight-related condition), and both were led from the same Fudan University endocrinology department. The gaps that remain: GEMINI-1 ran 4 weeks shorter, reported least-squares means under a treatment-policy estimand, and had a smaller placebo response (−1.4% vs −2.3%). On placebo-adjusted numbers the two top doses land about 1 point apart with overlapping confidence intervals (−18.4 to −14.2 for ribupatide 6 mg; −18.2 to −12.1 for tirzepatide 15 mg). That reads as "in the same range", not "beat".
The other part of the viral post, that weight loss showed "no clear plateau" at week 48, is not something the published abstract addresses: it reports week-48 values, not the shape of the curve. Treat that part as unverified until the full time-course is public.
Key Takeaways
- GEMINI-1 was a 48-week, double-blind, placebo-controlled phase 3 trial at 55 sites in China in 567 adults without diabetes (mean BMI 33.3, mean age 34.4).
- Mean weight change was −10.7%, −16.4% and −17.7% on 2, 4 and 6 mg, against −1.4% on placebo (P < .001 for all doses).
- At least 5% weight loss was reached by 68.1%, 88.0% and 85.7% of people on 2, 4 and 6 mg, versus 16.0% on placebo.
- The 4 mg and 6 mg doses landed close together: 16.4% vs 17.7% mean loss, and the 4 mg group had the higher 5% responder rate.
- Gastrointestinal events were the most common side effects and rose with dose; 0.7% of participants stopped treatment because of adverse events.
- 90.7% of participants completed the 48-week treatment period.
- How ribupatide compares with tirzepatide in the same trial: no head-to-head study has been published.
- Whether weight loss was still falling at week 48. The abstract reports week-48 values only, so the viral "no plateau" claim is unverified.
- How it performs outside China, in people with type 2 diabetes, or beyond 48 weeks.
- How much weight returns after stopping. In a SURMOUNT-CN follow-up, people who stopped tirzepatide regained 9.1% to 12.3% of body weight over 26 weeks; no such data exist yet for ribupatide.
- How much of the weight lost was fat versus lean mass. Body composition is not reported in the abstract.
- Long-term safety. The trial was sponsored by Hengrui, which helped design, analyse and write it up.
Frequently Asked Questions
What is ribupatide (HRS9531)?
Ribupatide, code name HRS9531, is an investigational once-weekly injection from Jiangsu Hengrui Pharmaceuticals. It activates both the GLP-1 and GIP receptors, the same dual-agonist approach as tirzepatide. Its first phase 3 obesity trial, GEMINI-1, was published in JAMA in November 2026.
How much weight did people lose on ribupatide in GEMINI-1?
At week 48, mean body weight fell 10.7% on 2 mg, 16.4% on 4 mg and 17.7% on 6 mg, compared with 1.4% on placebo. After subtracting placebo, that is 9.3, 15.0 and 16.3 percentage points. All participants also followed a lifestyle program.
Is ribupatide stronger than tirzepatide?
There is no direct answer yet. GEMINI-1 (ribupatide 6 mg, 17.7% at 48 weeks) and SURMOUNT-CN (tirzepatide 15 mg, 17.5% at 52 weeks) are separate trials with different lengths and placebo responses. Their placebo-adjusted results overlap, so the fair reading is that the top doses performed in a similar range.
What are the side effects of ribupatide?
Gastrointestinal events were the most frequent, reported by 47.9%, 58.2% and 63.1% of people on 2, 4 and 6 mg versus 23.1% on placebo. Most were mild to moderate, and only 0.7% of participants permanently stopped treatment because of side effects.
Can you get ribupatide?
Ribupatide is an investigational drug. The published evidence comes from clinical trials in China, and the JAMA report does not describe a marketing approval. Check its current status with the drug regulator in your country, and talk to a clinician about approved weight-loss options.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Ribupatide is an investigational drug studied in clinical trials. Do not source or self-administer it; discuss approved weight-loss treatments with a licensed clinician.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.